How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

185 results for

Subacute Lymphocytic Thyroiditis

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

62. Management of Multiple Sclerosis

Demyelinating Encephalomyelitis (ADEM) 47, level III; 63, level III • An acute autoimmune demyelinating disease of CNS • Triggered by viral infections and immunisations • Usually a monophasic course • Characterised by: ? subacute encephalopathy evolving over one week to three months, disturbance of consciousness and/or behavioural abnormality ? seizures or coma ? multifocal symptoms and signs: cerebellar or cerebral ? ON or TM ? MRI brain shows symmetrical multifocal or diffuse brain lesions - supra

2015 Ministry of Health, Malaysia

63. Childhood Hematopoietic Cell Transplantation (PDQ®): Health Professional Version

information). This approach to transplantation relies on GVL because, in most cases, the intensity of the preparative regimen is not sufficient for cure. Although studies have shown benefit for patients pursuing this approach when they are ineligible for standard transplantation,[ ] this approach has not been used for most children with cancer who require HCT because pediatric cancer patients can generally undergo myeloablative approaches safely. Using donor lymphocyte infusions (DLI) or early withdrawal (...) of immune suppression to enhance GVL GVL can be delivered therapeutically through the infusion of cells after transplant that either specifically or nonspecifically target the tumor. The most common approach is the use of DLI. This approach relies on the persistence of donor T-cell engraftment after transplant to prevent rejection of donor lymphocytes infused to induce the GVL. Therapeutic DLI results in potent responses in patients with CML who relapse after transplant (60%–80% enter into long-term

2016 PDQ - NCI's Comprehensive Cancer Database

64. 2013 ACCF/AHA Guideline for the Management of Heart Failure

and Metabolic Causes of Cardiomyopathy e250 5.3.1. Obesity e250 5.3.2. Diabetic Cardiomyopathy e250 5.3.3. Thyroid Disease e250 5.3.4. Acromegaly and Growth Hormone Deficiency e250 5.4. Toxic Cardiomyopathy e251 5.4.1. Alcoholic Cardiomyopathy e251 5.4.2. Cocaine Cardiomyopathy e251 5.4.3. Cardiotoxicity Related to Cancer Therapies e251 5.4.4. Other Myocardial Toxins and Nutritional Causes of Cardiomyopathy e251 5.5. Tachycardia-Induced Cardiomyopathy e251 5.6. Myocarditis and Cardiomyopathies Due

Full Text available with Trip Pro

2013 American Heart Association

65. Effectiveness of biological drugs for non NICE indications (licensed and unlicensed).

lymphocytic leukaemia for whom fluorabine combination chemotherapy is not appropriate Application of license for multiple sclerosis - - EMA withdrew the licence (15/08/2012) for EU In agreement with MHRA, Genzyme will Intravenous infusion SMC recommends restricted use http://www.scottishmedicines.org.uk /SMC_Advice/Advice/494_08_alemtu zumab__MabCampath_/alemtuzuma b__MabCampath_ http://www.ema.europa.eu/docs/en _GB/document_library/EPAR_- 4 Drug name Drug type Licensed indication Outcome NICE appraisal (...) ) Not recommended for use by SMC Rituximab (Mabthera) Monoclonal antibody For the treatment of non-Hodgkin’s lymphoma in adults, chronic lymphocytic leukaemia, and rheumatoid arthritis Follicular lymphoma patients receiving rituximab+ CVP chemotherapy lived 25.9 months without disease coming back. Patients who failed other treatments responded to rituximab In CLL patients, outcomes were better when they received rituximab In patients with RA, rituximab was more effective than placebo, rituximab had

2013 West Midlands Clinical Support Unit

66. Monitoring of Nonsteroidal Immunosuppressive Drugs in Patients With Lung Disease and Lung Transplant Recipients

demyelination. 40,62 Other possible toxicities include diabetic ketoacidosis, 63 hyperthyroidism, 64 thyroiditis, 65 GI dysfunction (vom- iting, abdominal pain, and cholecystitis), 40,66 blood dyscra- sias (ane mia, leukopenia, neutropenia, pancytopenia, thrombocytopenia, hemophagocytic syndrome), 40,66,67 septic arthritis, 68 optic neuritis, 69 cough, 40,70 viral pneu- monia, 71 and lymphoma. 40 In general, most of these toxicities are associations based on case reports or reports to the FDA Adverse Event

2012 American College of Chest Physicians

67. Management of suspected viral encephalitis in children

-infectious encephalitis, sub-acute encephalitis and sub-acute sclerosing panencephalitis Mumps virus Parotitis, orchitis or pancreatitis may occur before, during or after meningoencephalitis Others (rarer causes) Influenza viruses, adenovirus, Erythrovirus B19, lymphocytic choreomeningitis virus, rubella virus, Arthropod-borne and zoonotic viruses Flaviviruses (family Flaviviridae) West Nile virus North America, Southern Europe, Africa, Middle East, West and Central Asia associated with flaccid paralysis

Full Text available with Trip Pro

2012 British Infection Association

68. Hypothyroidism investigation and management

caused by autoimmune chronic lymphocytic thyroiditis. The initial screening for suspected hypothyroidism is thyroid stimulating hormone (TSH). A thyroid peroxidase antibody assay is the only test required to confirm the diagnosis of autoimmune thyroiditis. Thyroid ultrasonography is only indicated if there is a concern regarding structural thyroid abnormalities. Thyroid radionucleotide scanning has no role in the work-up for hypothyroidism. Treatment is with thyroxine replacement (1.6 µg/kg lean body (...) worldwide. 4 however, in Australia and other iodine replete countries, autoimmune chronic lymphocytic thyroiditis is the most common aetiology. 5 the main causes of hypothyroidism and associated clinical features are shown in Table 1. When to suspect hypothyroidism symptoms are influenced by the severity of the hypothyroidism, as well as its rapidity of onset. slow failure of thyroid function caused by autoimmune thyroiditis typically presents insidiously over years. 6 Where the diagnosis is suspected

2012 Clinical Practice Guidelines Portal

69. Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Clinical Effect of GSK2646264 in Cutaneous Lupus Erythematosus Subjects

Recruitment Status : Completed First Posted : October 7, 2016 Last Update Posted : August 13, 2018 Sponsor: GlaxoSmithKline Information provided by (Responsible Party): GlaxoSmithKline Study Details Study Description Go to Brief Summary: This study is designed to examine safety, tolerability, pharmacokinetics, pharmacodynamics and clinical effect of repeat dosing of GSK2646264 in patients with subacute and chronic cutaneous lupus erythematosus (CLE) lesions and in acute CLE like lesions induced (...) included are platelet count, red blood cell (RBC) count, hemoglobin, hematocrit, mean corpuscular volume (MCV), mean corpuscular hemoglobin (MCH), neutrophils, lymphocytes, monocytes, eosinophils, basophils. Number of participants with abnormal hematology parameters in Group B [ Time Frame: Approximately 12 weeks ] The hematology parameters included are platelet count, RBC count, hemoglobin, hematocrit, MCV, MCH, neutrophils, lymphocytes, monocytes, eosinophils, basophils. Number of participants

2016 Clinical Trials

70. Childhood Acute Myeloid Leukemia/Other Myeloid Malignancies Treatment (PDQ®): Health Professional Version

and Other Myeloid Malignancies in Children Approximately 20% of childhood leukemias are of myeloid origin and they represent a spectrum of hematopoietic malignancies.[ ] The majority of myeloid leukemias are acute, and the remainder include chronic and/or subacute myeloproliferative disorders such as chronic myelogenous leukemia and juvenile myelomonocytic leukemia. Myelodysplastic syndromes occur much less frequently in children than in adults and almost invariably represent clonal, preleukemic (...) are inhibited by fluoride. Immunophenotypic evaluation The use of monoclonal antibodies to determine cell-surface antigens of AML cells is helpful to reinforce the histologic diagnosis. Various lineage-specific monoclonal antibodies that detect antigens on AML cells should be used at the time of initial diagnostic workup, along with a battery of lineage-specific T-lymphocyte and B-lymphocyte markers to help distinguish AML from ALL and acute leukemias of ambiguous lineage. The expression of various cluster

2015 PDQ - NCI's Comprehensive Cancer Database

71. Thymoma and Thymic Carcinoma Treatment (PDQ®): Health Professional Version

disorders associated with thymoma include the following:[ , , ] - Acute pericarditis. - Addison disease. - Agranulocytosis. - Alopecia areata. - Cushing syndrome. - Hemolytic anemia. - Limbic encephalopathy. - Myocarditis. - Nephrotic syndrome. - Parahypopituitarism. - Pernicious anemia. - Aplastic anemia. - Polymyositis. - Rheumatoid arthritis. - Sarcoidosis. - Scleroderma. - Sensorimotor radiculopathy. - Sjögren syndrome. - Stiff-person syndrome. - Systemic lupus erythematosus. - Thyroiditis (...) . [ ] Cucchiara BL, Forman MS, McGarvey ML, et al.: Fatal subacute cytomegalovirus encephalitis associated with hypogammaglobulinemia and thymoma. Mayo Clin Proc 78 (2): 223-7, 2003. [ ] Morgenthaler TI, Brown LR, Colby TV, et al.: Thymoma. Mayo Clin Proc 68 (11): 1110-23, 1993. [ ] Souadjian JV, Enriquez P, Silverstein MN, et al.: The spectrum of diseases associated with thymoma. Coincidence or syndrome? Arch Intern Med 134 (2): 374-9, 1974. [ ] Thomas CR, Wright CD, Loehrer PJ: Thymoma: state of the art. J

2014 PDQ - NCI's Comprehensive Cancer Database

75. Evaluation of Sleep Apnea Related Inflammation With CRP, ESR and Neutrophil toLymphocyte Ratio

, diabetes mellitus, dyslipidemia, cardiovascular disease or hypertension, chronic inflammatory processes, thyroid dysfunction, chronic hepatic disease, renal failure, any acute- subacute infectious disease within past 2 months, if data are incomplete such as blood sample testing results, if they were unable to perform complete PSG testing. Contacts and Locations Go to No Contacts or Locations Provided More Information Go to Layout table for additonal information Responsible Party: Hakan Korkmaz (...) of nocturnal sleep disturbance and associated systemic inflammation and presence of comorbidities. Recently, novel inflammatory biomarkers, such as neutrophil to lymphocyte ratio (NLR) have been proposed as an indicator of systemic inflammation. To our knowledge, NLR has not been studied in OSAS. We conducted the present study to evaluate the association between OSAS and inflammatory markers CRP, ESR and NLR. Condition or disease Intervention/treatment Obstructive Sleep Apnea Other: Evaluation of Sleep

2014 Clinical Trials

76. Myeloid Leukemia, Childhood Acute/Other Childhood Myeloid Malignancies

rate increased over the same time from less than 20% to 68% for children younger than 15 years and from less than 20% to 57% for adolescents aged 15 to 19 years.[ ] Characteristics of Myeloid Leukemias and Other Myeloid Malignancies in Children Approximately 20% of childhood leukemias are of myeloid origin and they represent a spectrum of hematopoietic malignancies.[ ] The majority of myeloid leukemias are acute, and the remainder include chronic and/or subacute myeloproliferative disorders (...) - + + - - - - PAS - - ± ± + - + Immunophenotypic evaluation The use of monoclonal antibodies to determine cell-surface antigens of AML cells is helpful to reinforce the histologic diagnosis. Various lineage-specific monoclonal antibodies that detect antigens on AML cells should be used at the time of initial diagnostic workup, along with a battery of lineage-specific T-lymphocyte and B-lymphocyte markers to help distinguish AML from ALL and acute leukemias of ambiguous lineage. The expression of various cluster

2012 PDQ - NCI's Comprehensive Cancer Database

77. Thymoma and Thymic Carcinoma

. Nephrotic syndrome. Parahypopituitarism. Pernicious anemia. Aplastic anemia. Polymyositis. Rheumatoid arthritis. Sarcoidosis. Scleroderma. Sensorimotor radiculopathy. Sjögren syndrome. Stiff-person syndrome. Systemic lupus erythematosus. Thyroiditis. Ulcerative colitis. Prognosis and Survival Although the oncologic prognosis of thymoma is reported to be more favorable in patients with myasthenia gravis than in patients without myasthenia gravis,[ , ] data are conflicting as to whether the presence (...) (2): 123-33, 2001. Montella L, Masci AM, Merkabaoui G, et al.: B-cell lymphopenia and hypogammaglobulinemia in thymoma patients. Ann Hematol 82 (6): 343-7, 2003. Cucchiara BL, Forman MS, McGarvey ML, et al.: Fatal subacute cytomegalovirus encephalitis associated with hypogammaglobulinemia and thymoma. Mayo Clin Proc 78 (2): 223-7, 2003. Morgenthaler TI, Brown LR, Colby TV, et al.: Thymoma. Mayo Clin Proc 68 (11): 1110-23, 1993. Souadjian JV, Enriquez P, Silverstein MN, et al.: The spectrum

2012 PDQ - NCI's Comprehensive Cancer Database

78. Opsumit - macitentan

, the haemostatic system, thyroid, kidney, uterus, ovary and nasal cavity. Arterial intimal thickening characterized by proliferation of the intimal layer was found in dogs treated with macitentan at doses =30 mg/kg/day, independently of the treatment duration. The right and, less often, the left coronary arteries were the preferred target. These findings were often associated with breaks of the internal elastic lamina. After subacute (4-week) treatment with doses higher than 50 mg/kg/day, atrial fibrosis (...) toxicity studies. The changes were minimal, found at doses that indicate acceptable safety margins for humans (8.2 in rats, 5.8 in male dogs and 17 in female dogs) and reversible. A prolonged aPTT was observed in male rats treated with 250 mg/kg/day during 13 or 26 weeks. The finding is considered to have limited relevance to humans as it was observed only at high dose levels that provide safety margins higher than 7, in only one species and only in males. The observed increased thyroid weight

2013 European Medicines Agency - EPARs

79. Lemtrada - alemtuzumab

to high-dose, high-frequency IFNB-1a, nor was it formally studied in patients experiencing disease activity on another MS treatment. The active substance, alemtuzumab, is a humanized monoclonal antibody directed against CD52, one of several specific surface antigens acquired by cells of the hematopoietic system during leukocyte differentiation. Alemtuzumab binds to CD52 which is present at high levels on the surface of T and B lymphocytes and at lower levels on natural killer cells, monocytes (...) and macrophages. There is little or no CD52 detected on neutrophils, plasma cells or bone marrow stem cells. Alemtuzumab was approved until recently as MabCampath for the treatment of B-cell chronic lymphocytic leukemia. The posology, however, is considerably different for MS as compared to B- CLL: the cumulative dose in B-CLL was around 1100 mg, administered in a dose escalation scheme within 12 weeks, while in MS the cumulative dose is much lower: a maximum cumulative dose of 96 mg, administered in two

2013 European Medicines Agency - EPARs

80. Erivedge - vismodegib

/atrophy of odontoblasts and ameloblasts, degradation of dentin with scattered sequestrae, formation of fluid-filled cysts in the dental pulp, hyperplasia of the periodontal ligament, ossification of the root canal, regeneration of the dental organ, occasional fibrometaplasia, and scattered haemorrhage and subacute inflammation. The majority of these changes persisted in recovery animals. 07-1224 GLP Rat 10M/10F 26 weeks + 10M/10F 8 weeks recovery, 10M/10F 0 15 50 100 BID A dose-related, reversible

2013 European Medicines Agency - EPARs

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>